» Articles » PMID: 2168910

Rett Syndrome: a Mitochondrial Disease?

Overview
Journal J Child Neurol
Specialties Neurology
Pediatrics
Date 1990 Jul 1
PMID 2168910
Citations 23
Authors
Affiliations
Soon will be listed here.
Abstract

Six girls between 2 years 9 months and 15 years of age with Rett syndrome were thoroughly investigated. Blood ammonia levels varied between 42 and 123 mumol/L, and serum lactate concentration was slightly elevated in two girls. Electroencephalograms showed a dysrhythmic pattern during wakefulness; during drowsiness and light sleep, bilateral bursts of spike or multispike-and-wave activity were seen in all but the oldest girl. In one of the younger girls, slight cortical atrophy was found on computed tomographic scan. Muscle biopsy was performed on all girls, and electron microscopy revealed abnormal mitochondria. Physical signs such as somatic hypotrophy with extremely small muscle mass, and unsatisfactory weight gain in spite of good appetite are found in Rett syndrome. These attributes, as well as reports of ornithine carbamoyltransferase deficiency, may support a mitochondrial dysfunction. The mitochondrial changes indicate either a mitochondrial mutation or more probably an X-borne modulator gene mutation. Another genetic possibility discussed is the "metabolic interference" of an X-borne allele. Further delineation of such mitochondrial changes may clarify the causal metabolic defect in Rett syndrome.

Citing Articles

Molecular Mechanisms of Rett Syndrome: Emphasizing the Roles of Monoamine, Immunity, and Mitochondrial Dysfunction.

Goncalez J, Shen J, Li W Cells. 2025; 13(24.

PMID: 39768168 PMC: 11674639. DOI: 10.3390/cells13242077.


Multilevel evidence of MECP2-associated mitochondrial dysfunction and its therapeutic implications.

Balicza P, Gezsi A, Fedor M, Sagi J, Gal A, Varga N Front Psychiatry. 2024; 14:1301272.

PMID: 38250256 PMC: 10796460. DOI: 10.3389/fpsyt.2023.1301272.


Mitochondrial Proteome Changes in Rett Syndrome.

Golubiani G, van Agen L, Tsverava L, Solomonia R, Muller M Biology (Basel). 2023; 12(7).

PMID: 37508386 PMC: 10376342. DOI: 10.3390/biology12070956.


Effects of the Rho GTPase-activating toxin CNF1 on fibroblasts derived from Rett syndrome patients: A pilot study.

Cittadini C, Germinario E, Maroccia Z, Cosentino L, Maselli V, Gambardella L J Cell Mol Med. 2023; 27(10):1315-1326.

PMID: 37078409 PMC: 10183712. DOI: 10.1111/jcmm.17624.


Oral Feeding of an Antioxidant Cocktail as a Therapeutic Strategy in a Mouse Model of Rett Syndrome: Merits and Limitations of Long-Term Treatment.

Baroncelli L, Auel S, Rinne L, Schuster A, Brand V, Kempkes B Antioxidants (Basel). 2022; 11(7).

PMID: 35883897 PMC: 9311910. DOI: 10.3390/antiox11071406.